|
|
News Breaks | | | | January 6, 2013 | | 11:49 EDT |  | AMAG | AMAG sees FY13 COGS of between 14% and 18% of net product sales
AMAG sees FY13 cost of goods sold, COGS, of between 14% and 18% of net product sales; Total operating expenses, excluding COGS, of between $78M and $82M, representing an approximate 10% reduction from 2012. The reduced operating expenses in 2013 will be driven by decreased clinical trial costs, offset in part by new investments in a lower-cost production process and pre-launch investments to support a potential expansion to Feraheme’s label. The company expects: Research and development expenses of between $24M and $27M, representing an approximate 27% reduction from 2012; Selling, general and administrative expenses of between $54M and $57M, representing an approximate 2% increase from 2012. | |
|
News For AMAG From The Last 14 Days Check below for free stories on AMAG the last two weeks. |
|
|
| May 15, 2013 | | 09:53 EDT |  | AMAG | AMAG Pharmaceuticals management to meet with Leerink
 Subscribe for More Information | |
|
|
|
|
|
|
